SCHEMBL31172622

SCHEMBL31172622

O=C(Oc1c(F)c(F)c(F)c(F)c1F)c1ccc(Cn2cccn2)c(C2CC2)c1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ BRD4 O60885 1/20 0.35
▸ KLKB1 P03952 2/20 0.35
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ KAT7 O95251 3/20 0.33
▸ KAT6A Q92794 3/20 0.33
▸ HTT P42858 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ KAT6B Q8WYB5 2/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ HRH3 Q9Y5N1 3/20 0.33
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172624 1.00 CNR1 (0.36) CNR1CNR2BRD4KLKB1MEN1
SCHEMBL31172526 0.90 KLKB1 (0.39) CNR1CNR2BRD4KLKB1MEN1
SCHEMBL31172570 0.85 HTT (0.41) CNR1CNR2BRD4KLKB1MEN1
SCHEMBL31172742 0.81 ALDH1A1 (0.35) CNR1CNR2BRD4KLKB1MEN1
SCHEMBL31172565 0.80 KAT7 (0.40) BRD4KLKB1MEN1KMT2AKAT7
SCHEMBL31516714 0.76 KAT7 (0.50) KAT7KAT6AKAT6B
SCHEMBL31172590 0.73 KLKB1 (0.41) BRD4KLKB1MEN1KMT2AKAT7
SCHEMBL31172554 0.73 KAT7 (0.42) MEN1KMT2AKAT7KAT6AHTT
SCHEMBL31172540 0.73 HDAC1 (0.42) BRD4KLKB1MEN1KMT2AKAT7
SCHEMBL31172572 0.72 KLKB1 (0.41) BRD4KLKB1MEN1KMT2AKAT7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B CNR1 4166/4885CNR2 4380/4885BRD4 426/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B CNR1 4166/4885CNR2 4380/4885BRD4 426/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B CNR1 1062/4885CNR2 2827/4885BRD4 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback